Navigation Links
Curemark Appoints Jennifer Katritos, CPA as Vice President of Finance
Date:12/13/2010

RYE, N.Y., Dec. 13, 2010 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has appointed Jennifer Katritos, CPA, as vice president of finance, the company announced.  She joined Curemark in July, 2009 as director of finance.  Katritos oversees Curemark's financial function, responsible for financial planning and reporting and risk analysis.

During her 20-year career, Katritos has held a variety of financial positions, primarily in the research-focused nonprofit sector.  Prior to Curemark, she served as director of finance for the Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium.  Previously, Katritos headed her own financial consulting practice with a focus on nonprofit and emerging businesses.

"We are extremely pleased about Jennifer's well-deserved and well-earned promotion," said Joan Fallon, Curemark founder and CEO.  "She came to Curemark with a stellar financial background and extensive experience in the research space.  She has exhibited strong leadership in the financial arena."  

"It has been incredibly rewarding to utilize my financial expertise in a way that helps individuals in need.  I am particularly thrilled to be working with Joan and the Curemark team," Katritos said.  "I am inspired by their dedication to help children and families with the pervasive issue of autism."

Katritos began her career with Deloitte and Touche LLP in New York.  She holds a BS in Accounting and Finance from the State University of New York at Oneonta.

Curemark is currently in Phase III clinical trials for CM-AT, an autism treatment which has received Fast Track status from the FDA.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... data and benchmarks in the global Fibromyalgia market. The ... the key drugs marketed for Fibromyalgia and their clinical attributes? How ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)...  MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... to develop and market advanced products and therapies for ... and Dental sectors of healthcare, today announced its record ... December 31, 2016. Full Year 2016 Highlights ... increase over full year 2015 revenue ...
Breaking Medicine Technology:
(Date:2/23/2017)... Denver, Colorado (PRWEB) , ... February 23, 2017 ... ... Dialog Magazine, an exciting, new, interactive publication where generations converge and explore the ... to expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, ...
(Date:2/23/2017)... ... (PRWEB) February 23, ... the nation to come together to combine its favorite springtime ... its favorite fruit – apples! To celebrate National Nutrition Month, ... the “Apple Madness” bracket tournament – a five-week, five-round online ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy has ... technology is so cutting edge, in fact, the U.S. Food and Drug Administration ... However, successful patient outcomes in certain clinical stem cell procedures have shown that ...
(Date:2/22/2017)... ... 2017 , ... Giving patients with diabetes customized coaching sessions, ... hospital admissions, and better blood pressure and glycemic control, a new study ... be found here . , The study comes as health plans increasingly ...
Breaking Medicine News(10 mins):